BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...of a cancer vaccine developed more than a decade ago by co-founder Emile Loria at Epimmune Inc....
...PADRE universal helper T lymphocyte epitope as an immunostimulant. Details were not disclosed. Loria was Epimmune's...
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...vaccine initially developed more than a decade ago by co-founder Emile Loria at San Diego-based Epimmune Inc....
...in discussions with potential investors to raise EUR 2-EUR 5 million ($2.5-$6.2 million). Loria was Epimmune's...
BioCentury | Apr 25, 2011
Company News

Biotech Synergy deal

...of EP-2101 in the indication. Further terms were not disclosed. EP-2101 was originally developed by Epimmune Inc....
BioCentury | May 31, 2010
Finance

Performance Counts

...AG $16 Platform: drug delivery Diractin ketoprofen (IDEA-033) [IDEA] NA Immuno-Designed Molecules S.A., merged with Epimmune Inc....
BioCentury | May 4, 2009
Company News

Pharmexa, Kael Co. Ltd. deal

...Kael's VaxOnco Inc. subsidiary will acquire Pharmexa's Pharmexa- Epimmune Inc. subsidiary for € 440,000 ($579,436). VaxOnco gains...
...epitopes for HPV, HCV, HBV, HIV, malaria and cancer, plus an epitope identification system and Pharmexa-Epimmune's...
BioCentury | Dec 11, 2008
Targets & Mechanisms

Ad out

...the whole story," said Hertz, who is the former CEO of vaccine company Pharmexa - Epimmune...
BioCentury | Jan 31, 2008
Targets & Mechanisms

Simply irresistible

...colleagues believe-a BNAb-eliciting vaccine might be effective. According to Marc Hertz, CEO of Pharmexa - Epimmune Inc....
...would then switch focus to designing a vaccine appropriate for development," Hertz said. Pharmexa - Epimmune...
BioCentury | Jun 5, 2007
Clinical News

IDM presents interim NSCLC Phase II data

...antigens, plus the PADRE universal HTL epitope as an immunostimulant, through its 2005 acquisition of Epimmune...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...looked across the Atlantic and concluded a reverse merger with infectious disease and cancer company Epimmune Inc....
...a U.S. listing would improve the company's access to capital. In addition, Romet-Lemonne had seen Epimmune's...
...Epimmune's infectious disease assets to Pharmexa A/S (CSE:PHARMX, Horsholm, Denmark). But in hindsight, Romet-Lemonne said Epimmune...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...floating on SWX or the LSE, but decided to head to NASDAQ by reverse-merging with Epimmune Inc....
...internal private round prior to the merger and has since raised $12 million by selling Epimmune’s...
Items per page:
1 - 10 of 160
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...of a cancer vaccine developed more than a decade ago by co-founder Emile Loria at Epimmune Inc....
...PADRE universal helper T lymphocyte epitope as an immunostimulant. Details were not disclosed. Loria was Epimmune's...
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...vaccine initially developed more than a decade ago by co-founder Emile Loria at San Diego-based Epimmune Inc....
...in discussions with potential investors to raise EUR 2-EUR 5 million ($2.5-$6.2 million). Loria was Epimmune's...
BioCentury | Apr 25, 2011
Company News

Biotech Synergy deal

...of EP-2101 in the indication. Further terms were not disclosed. EP-2101 was originally developed by Epimmune Inc....
BioCentury | May 31, 2010
Finance

Performance Counts

...AG $16 Platform: drug delivery Diractin ketoprofen (IDEA-033) [IDEA] NA Immuno-Designed Molecules S.A., merged with Epimmune Inc....
BioCentury | May 4, 2009
Company News

Pharmexa, Kael Co. Ltd. deal

...Kael's VaxOnco Inc. subsidiary will acquire Pharmexa's Pharmexa- Epimmune Inc. subsidiary for € 440,000 ($579,436). VaxOnco gains...
...epitopes for HPV, HCV, HBV, HIV, malaria and cancer, plus an epitope identification system and Pharmexa-Epimmune's...
BioCentury | Dec 11, 2008
Targets & Mechanisms

Ad out

...the whole story," said Hertz, who is the former CEO of vaccine company Pharmexa - Epimmune...
BioCentury | Jan 31, 2008
Targets & Mechanisms

Simply irresistible

...colleagues believe-a BNAb-eliciting vaccine might be effective. According to Marc Hertz, CEO of Pharmexa - Epimmune Inc....
...would then switch focus to designing a vaccine appropriate for development," Hertz said. Pharmexa - Epimmune...
BioCentury | Jun 5, 2007
Clinical News

IDM presents interim NSCLC Phase II data

...antigens, plus the PADRE universal HTL epitope as an immunostimulant, through its 2005 acquisition of Epimmune...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...looked across the Atlantic and concluded a reverse merger with infectious disease and cancer company Epimmune Inc....
...a U.S. listing would improve the company's access to capital. In addition, Romet-Lemonne had seen Epimmune's...
...Epimmune's infectious disease assets to Pharmexa A/S (CSE:PHARMX, Horsholm, Denmark). But in hindsight, Romet-Lemonne said Epimmune...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...floating on SWX or the LSE, but decided to head to NASDAQ by reverse-merging with Epimmune Inc....
...internal private round prior to the merger and has since raised $12 million by selling Epimmune’s...
Items per page:
1 - 10 of 160